Position in LQDA
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$1,291,538
+$1,291,538 QoQ
Shares Held
34,222
Ownership
0.038%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Derivatives in LQDA
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$524,586
PutShares
13,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026CAPITAL FUND MANAGEMENT S.A. holds $92,308,096 across 12 Drug Manufacturers - Specialty & Generic names. LQDA ranks #8 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
48,964 | $29,034,672 | |
| 2 | ZTS |
Zoetis Inc.
|
190,415 | $22,508,957 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
149,631 | $19,712,387 | |
| 4 | ALKS |
Alkermes plc.
|
243,043 | $8,594,000 | |
| 5 | HLN |
Haleon plc
|
421,051 | $4,214,720 | |
| 6 | PRGO |
PERRIGO Co plc
|
277,003 | $2,975,012 | |
| 7 | SUPN |
Supernus Pharmaceuticals, Inc.
|
29,715 | $1,535,968 | |
| 8 | LQDA |
Liquidia Corp
This page
|
34,222 | $1,291,538 |
All Filings in LQDA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,291,538 | 34,222 | Shares | Sole | 2026-05-14 | |
| 2026-03-31 | $524,586 | 13,900 | Put | Sole | 2026-05-14 | |
| 2025-12-31 | $1,007,108 | 29,200 | Call | Sole | 2026-02-17 | |
| 2025-12-31 | $965,720 | 28,000 | Put | Sole | 2026-02-17 | |
| 2025-09-30 | $361,566 | 15,900 | Call | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||